A groundbreaking study has revealed that patients diagnosed with frontotemporal dementia (FTD) experience epileptic seizures at a rate significantly higher than previously estimated by the medical community. This discovery, which stems from one of the most comprehensive datasets ever compiled on the subject, is poised to reshape the clinical understanding of FTD, a complex and often devastating memory disorder. By highlighting a much stronger link between neurodegeneration and electrical instability in the brain, the research emphasizes the urgent need for integrated neurological monitoring and specialized treatment protocols for those living with the condition.
The study was a collaborative effort coordinated by Neurocenter Finland, involving a deep partnership between the University of Eastern Finland and the University of Oulu. The findings, which have been published in the prestigious medical journal JAMA Neurology, provide a new lens through which clinicians can view the progression of FTD. Traditionally, the focus of FTD research and care has remained on its profound impact on personality, behavior, and language. However, these new results suggest that the "electrical health" of the brain is a critical, yet frequently overlooked, component of the disease’s pathology.
Frontotemporal dementia represents a group of brain disorders that primarily affect the frontal and temporal lobes of the brain. These areas are generally associated with personality, behavior, and language. Unlike Alzheimer’s disease, which typically presents with memory loss as its earliest symptom, FTD often manifests as dramatic changes in social conduct or a decline in linguistic abilities. Because the symptoms are so heavily centered on behavior, the co-occurrence of epilepsy has often been obscured or attributed to other causes. This study effectively fills a significant gap in global medical literature, providing the empirical evidence needed to prioritize seizure screening in this patient population.
The research team analyzed an extensive array of patient data sourced from the university hospitals of Kuopio and Oulu, covering a broad window from 2010 to 2021. To ensure the robustness of their findings, the researchers examined a massive dataset comprising 12,490 medical records. Within this pool, they identified 245 patients with frontotemporal dementia and 1,326 patients with Alzheimer’s disease. By comparing these groups not only against each other but also against healthy controls, the study was able to isolate the specific prevalence of epilepsy within the FTD cohort with unprecedented clarity.
Epilepsy occurred years before the FTD diagnosis
One of the most striking revelations of the study is the chronological relationship between the onset of epilepsy and the eventual diagnosis of frontotemporal dementia. While it has long been established that epilepsy is a common comorbidity in Alzheimer’s disease due to the accumulation of amyloid plaques and tau tangles that disrupt neural signaling, data regarding the connection between FTD and epilepsy has remained scarce until now. The findings from the University of Eastern Finland and the University of Oulu show that the prevalence of epilepsy in FTD patients is not only higher than previously thought but also higher than that observed in patients with Alzheimer’s disease.
"Our results show that epilepsy is considerably more common among those with FTD than those with Alzheimer’s disease or in healthy controls," says Doctoral Researcher Annemari Kilpeläinen, the first author of the research article and a medical specialist in neurology. This comparative data is vital for neurologists who may have previously assumed that seizure activity was a secondary concern in FTD compared to other forms of dementia.
Perhaps even more significant for early intervention is the timing of these seizures. The research indicated that epilepsy often serves as a precursor to the more recognizable symptoms of dementia. "It is noteworthy that epilepsy occurred in some patients with FTD already ten years before their dementia diagnosis," Kilpeläinen notes. This suggests that for some individuals, the electrical instability of the brain may be one of the earliest signs of the underlying neurodegenerative process. The study found that epilepsy was more common across every stage of the disease—from the prodromal phase to the advanced stages—than any previous international studies had reported.
To quantify this progression, the researchers assessed the prevalence of epilepsy at several specific time points, ranging from a decade before the dementia diagnosis to five years following it. The data showed a clear upward trajectory: as the neurodegeneration associated with FTD progressed, so too did the likelihood of developing epilepsy. By the five-year mark following an FTD diagnosis, approximately 11% of patients had been diagnosed with epilepsy.
To ensure the accuracy of these figures, the researchers did not rely solely on formal epilepsy diagnoses. They also tracked the administration of anti-epileptic medications among the patient groups. The fact that the use of these medications was significantly higher in the FTD group further validates the study’s conclusions, suggesting that the seizures were frequent and severe enough to require pharmaceutical intervention. This multi-layered approach to data collection—combining diagnostic codes with medication history—strengthens the reliability of the results and underscores the magnitude of the issue.
Epilepsy might be left undiagnosed
The high prevalence of epilepsy in FTD patients brings to light a significant clinical hurdle: the difficulty of accurate diagnosis. In a patient already suffering from the behavioral or cognitive symptoms of frontotemporal dementia, a seizure may not look like the "grand mal" or tonic-clonic seizure typically associated with epilepsy in the popular imagination. Instead, these patients may experience focal seizures that manifest as sudden pauses in speech, repetitive movements, or brief periods of confusion—symptoms that are easily mistaken for the standard progression of FTD.
This overlap in symptoms creates a diagnostic "blind spot" that can lead to significant delays in treatment. When epileptic activity goes unrecognized, it is often left untreated, which can have a cascading effect on the patient’s overall health. Frequent, uncontrolled seizures can accelerate cognitive decline, increase the risk of physical injury from falls, and place an immense additional burden on caregivers.
"Identifying epilepsy is important because its treatment can improve patients’ functional capacity and quality of life," explains Associate Professor Eino Solje, the project’s principal investigator and Director of the University of Eastern Finland (UEF) Brain Research Unit. By stabilizing the electrical activity in the brain through appropriate medication, clinicians may be able to preserve a patient’s ability to perform daily tasks for a longer period, thereby extending their independence.
Beyond the immediate clinical benefits of treatment, the discovery opens up new frontiers for scientific inquiry. The strong correlation between the two conditions suggests that they may not be separate entities, but rather different manifestations of the same underlying problem. "Knowledge about the association between epilepsy and FTD raises new research questions: do these diseases share some pathophysiological mechanisms and could some FTD symptoms be caused by alterations in the specific electrical systems of the brain?" Solje asks.
This line of questioning points toward a potential shift in how neurodegenerative diseases are studied. If certain symptoms of FTD are actually the result of localized electrical disturbances rather than permanent tissue loss, there may be new opportunities for symptom management that have not yet been fully explored. Understanding the shared pathways between epilepsy and FTD could eventually lead to the development of therapies that target both the structural and electrical aspects of the disease simultaneously.
An extensive research project brings together different fields of science
The success of this study is largely attributed to its unique, interdisciplinary structure. Rather than being confined to a single laboratory or department, the project was a massive undertaking that bridged multiple institutions and fields of expertise. By combining extensive real-life patient data with unique national registers, the researchers were able to create a high-resolution map of the patient experience over more than a decade.
The collaboration between the University of Oulu and the University of Eastern Finland was central to the project’s success, allowing for a dataset that is among the largest of its kind in the world. However, the scope of the project went beyond clinical medicine. It also involved researchers from the field of law, reflecting the complex ethical and legal considerations involved in managing long-term neurodegenerative care and the use of sensitive patient data from hospital registers. This holistic approach ensures that the findings are not only scientifically sound but also grounded in the practical realities of healthcare systems and patient rights.
The involvement of the university hospitals in Kuopio and Oulu also lends the study significant international weight. Both institutions are members of the European Reference Network EpiCARE, a prestigious group of recognized centers dedicated to the treatment and research of rare and complex epilepsies. This connection ensures that the findings from this Finnish cohort will be disseminated across the global medical community, influencing care standards far beyond the borders of Northern Europe.
As the medical community digests these findings, the focus must now turn toward implementation. The study serves as a call to action for neurologists and geriatricians to incorporate seizure monitoring into the standard care of FTD patients. Early detection of epilepsy, particularly in those who have not yet reached the diagnostic threshold for dementia, could provide a critical window for intervention.
Ultimately, this research underscores the fact that frontotemporal dementia is a multi-faceted disorder that requires a comprehensive, multidisciplinary approach to care. By recognizing and treating the "hidden" epilepsy within the FTD population, healthcare providers can offer patients a better quality of life and a more manageable disease trajectory. The insights gained from this large-scale Finnish project mark a major step forward in the global effort to understand and treat the complexities of the human brain in the face of neurodegeneration.
